Browse by author
Lookup NU author(s): Professor Miles WithamORCiD
This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).
Copyright: © 2024 Flores-Flores et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.Introduction Sarcopenia and sarcopenic obesity (SO) have emerged as significant contributors to negative health outcomes in the past decade. We aimed to estimate the prevalence of probable sarcopenia, sarcopenia, and SO in a community-dwelling population of 1151 adults aged ≥55 years in Lima, Peru. Methods This cross-sectional study was conducted between 2018 and 2020. Sarcopenia was defined as the presence of low muscle strength (LMS) and low muscle mass (LMM) according to European (EWGSOP2), US (FNIH) and Asian (AWGS2) guidelines. We measured muscle strength by maximum handgrip strength and muscle mass using bioelectrical impedance analyzer. SO was defined as a body mass index ≥ 30 kg/m2 and sarcopenia. Results The study participants had a mean age of 66.2 years (SD 7.1), age range between 60 to 92 years old, of which 621 (53.9%) were men. Among the sample, 41.7% were classified as obese (BMI ≥30.0 kg/m2). The prevalence of probable sarcopenia was estimated to be 22.7% (95%CI: 20.3-25.1) using the EWGSOP2 criteria and 27.8% (95%CI: 25.2-30.4) using the AWGS2 criteria. Sarcopenia prevalence, assessed using skeletal muscle index (SMI), was 5.7% (95%CI: 4.4-7.1) according to EWGSOP2 and 8.3% (95%CI: 6.7-9.9) using AWGS2 criteria. The prevalence of sarcopenia based on the FNIH criteria was 18.1% (95%CI: 15.8-20.3). The prevalence of SO, considering different sarcopenia definitions, ranged from 0.8% (95%CI: 0.3-1.3) to 5.0% (95%CI: 3.8-6.3). Conclusion Our findings reveal substantial variation in the prevalence of sarcopenia and SO, underscoring the necessity for context-specific cut-off values. Although the prevalence of SO was relatively low, this result may be underestimated. Furthermore, the consistently high proportion of probable sarcopenia and sarcopenia point to a substantial public health burden.
Author(s): Flores-Flores O, Zevallos-Morales A, Pollard SL, Checkley W, Siddharthan T, Hurst JR, Bernabe-Ortiz A, Runzer-Colmenares FM, Witham MD, Parodi JF
Publication type: Article
Publication status: Published
Journal: PLoS ONE
Year: 2024
Volume: 19
Issue: 4
Online publication date: 09/04/2024
Acceptance date: 25/02/2024
Date deposited: 03/04/2024
ISSN (electronic): 1932-6203
Publisher: Public Library of Science
URL: https://doi.org/10.1371/journal.pone.0300224
DOI: 10.1371/journal.pone.0300224
Data Access Statement: The dataset used in our study is a part of the Global Excellence for COPD outcomes (GECO). The Principal Investigator of the GECO study, Professor John Hurst from University College London, is a co-author of this manuscript. Professor Hurst also serves as the President of the Steering Committee for the study. Formal verification of permission to use the dataset is not applicable in this context.We confirm that there were no special privileges granted to us in accessing the GECO data. The dataset was accessed following standard procedures that are available to all interested researchers. Our use of the data did not involve any exclusive or preferential treatment. Researchers who meet the criteria for access confidential data and are interested in accessing the GECO dataset can direct their requests to Professor John Hurst at University College London. He can be contacted via email at j.hurst@ucl.ac.uk. [Further details at https://doi.org/10.1371/journal.pone.0300224 ]
PubMed id: 38593158
Altmetrics provided by Altmetric
